Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer
10.1002/14651858.cd002093.pub2
Crossref reference-entry
John Wiley & Sons, Ltd
Cochrane Database of Systematic Reviews (311)
Bibliography

Yip, D., Karapetis, C., Strickland, A., Steer, C. B., & Goldstein, D. (2006). Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database of Systematic Reviews.

Authors 5
  1. Desmond Yip (first)
  2. Christos Karapetis (additional)
  3. Andrew Strickland (additional)
  4. Christopher B Steer (additional)
  5. David Goldstein (additional)
References 153 Referenced 55
  1. 10.3109/00365528109181013 / Scandinavian Journal of Gastroenterology / A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer by Andersen (1981)
  2. 10.3109/00365528309181646 / Scandinavian Journal of Gastroenterology / Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU by Andren-Sandberg (1983)
  3. 10.1200/JCO.2002.11.149 / Journal of Clinical Oncology / Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 by Berlin (2002)
  4. 10.1002/1097-0142(19831101)52:9<1577::AID-CNCR2820520906>3.0.CO;2-8 / Cancer / Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study by Bukowski (1983)
  5. 10.1002/1097-0142(197910)44:4<1215::AID-CNCR2820440408>3.0.CO;2-S / Cancer / 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study by Buroker (1979)
  6. 10.1016/S0959-8049(96)00324-3 / European Journal of Cancer / Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil by Burris (1997)
  7. 10.1200/JCO.1997.15.6.2403 / Journal of Clinical Oncology / Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial by Burris (1997)
  8. 10.1179/joc.2004.16.6.589 / Journal of Chemotherapy / Gemcitabine versus FLEC regimen given intraarterially to patients with unresectable pancreatic cancer: a prospective, randomised phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology by Cantore (2004)
  9. {'issue': '(4 Suppl)', 'key': '10.1002/14651858.CD002093.pub2-BIB9|cit9', 'first-page': '51', 'article-title': 'Randomised trial of gemcitabine versus FLEC regimen given intra-arterially for patients with unresectable pancreatic cancer', 'volume': '22', 'author': 'Cantore', 'year': '2003', 'journal-title': 'Journal of Experimental and Clinical Cancer Research'} / Journal of Experimental and Clinical Cancer Research / Randomised trial of gemcitabine versus FLEC regimen given intra-arterially for patients with unresectable pancreatic cancer by Cantore (2003)
  10. {'key': '10.1002/14651858.CD002093.pub2-BIB10|cit10', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4005', 'article-title': 'Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC)', 'author': 'Cheverton', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC) by Cheverton (2004)
  11. 10.1148/84.5.843 / Radiology / Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation by Childs (1965)
  12. 10.1002/cncr.10323 / Cancer / Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale by Colucci (1999)
  13. 10.1001/jama.1985.03350380077025 / JAMA / A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin by Cullinan (1985)
  14. 10.1001/jama.1985.03350380077025 / Jama / A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin by Cullinan (1985)
  15. 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y / Cancer / A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin by Cullinan (1990)
  16. 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y / Cancer / A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. by Cullinan (1990)
  17. 10.1093/annonc/mdf197 / Annals of Oncology / A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma by Ducreux (2002)
  18. {'key': '10.1002/14651858.CD002093.pub2-BIB18|cit18', 'first-page': '274a', 'article-title': 'Efficacy of 5FU+cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): a randomised trial conducted by the digestive group from the French Anticancer centres (FNLCC)', 'volume': '18', 'author': 'Rougier', 'year': '1999', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Efficacy of 5FU+cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): a randomised trial conducted by the digestive group from the French Anticancer centres (FNLCC) by Rougier (1999)
  19. 10.1093/annonc/mdh098 / Annals of Oncology / Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients by Ducreux (2004)
  20. 10.1016/0360-3016(94)90159-7 / International Journal of Radiation Oncology, Biology, Physics / Evaluation of external-beam radiation therapy plus 5-fluorouracil (5- FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer by Earle (1994)
  21. 10.1002/1097-0142(19810101)47:1<27::AID-CNCR2820470106>3.0.CO;2-F / Cancer / Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group by Frey (1981)
  22. 10.1007/s00423-001-0267-5 / Langenbecks Archives of Surgery / NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial by Gansauge (2002)
  23. 10.1002/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0 / Cancer / Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group (1985)
  24. 10.1093/jnci/80.10.751 / Journal of the National Cancer Institute / Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. (1988)
  25. 10.1093/oxfordjournals.annonc.a010676 / Annals of Oncology / Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer by Glimelius (1996)
  26. {'issue': '3', 'key': '10.1002/14651858.CD002093.pub2-BIB26|cit26', 'first-page': '164', 'article-title': 'Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial', 'volume': '32', 'author': 'Hazel', 'year': '1981', 'journal-title': 'Journal of the Canadian Association of Radiologists'} / Journal of the Canadian Association of Radiologists / Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial by Hazel (1981)
  27. {'key': '10.1002/14651858.CD002093.pub2-BIB27|cit27', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 1003', 'article-title': 'A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma', 'author': 'Heinemann', 'year': '2003'} / Proceedings of the American Society of Clinical Oncology / A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma by Heinemann (2003)
  28. {'key': '10.1002/14651858.CD002093.pub2-BIB28|cit28', 'first-page': 'Abstract 625', 'article-title': 'Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: Preliminary results of a randomized phase III trial', 'volume': '20', 'author': 'Heinemann', 'year': '2001', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: Preliminary results of a randomized phase III trial by Heinemann (2001)
  29. {'key': '10.1002/14651858.CD002093.pub2-BIB29|cit29', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract LBA401', 'article-title': 'Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)', 'author': 'Herrmann', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology / Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) by Herrmann (2005)
  30. {'issue': '1-2', 'key': '10.1002/14651858.CD002093.pub2-BIB30|cit30', 'first-page': '65', 'article-title': 'Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas', 'volume': '65', 'author': 'Horton', 'year': '1981', 'journal-title': 'Cancer Treatment Reports'} / Cancer Treatment Reports / Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas by Horton (1981)
  31. {'issue': '39', 'key': '10.1002/14651858.CD002093.pub2-BIB31|cit31', 'first-page': '875', 'article-title': 'Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer', 'volume': '48', 'author': 'Huguier', 'year': '2001', 'journal-title': 'Hepatogastroenterology'} / Hepatogastroenterology / Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer by Huguier (2001)
  32. 10.1002/1097-0142(19910901)68:5<965::AID-CNCR2820680509>3.0.CO;2-2 / Cancer / A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma by Kelsen (1991)
  33. 10.1200/JCO.1985.3.3.373 / Journal of Clinical Oncology / Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study by Klaassen (1985)
  34. 10.1002/1097-0142(197402)33:2<563::AID-CNCR2820330235>3.0.CO;2-K / Cancer / Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1- nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer by Kovach (1974)
  35. {'key': '10.1002/14651858.CD002093.pub2-BIB35|cit35', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4117', 'article-title': 'Chronomodulated (Chrono) vs constant (Cst) rate infusional 5-fluorouracil (FU) with or without cisplatin (CDDP) in patients with advanced or metastatic pancreatic cancer. A multicenter randomized trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05962)', 'author': 'Levi', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / Chronomodulated (Chrono) vs constant (Cst) rate infusional 5-fluorouracil (FU) with or without cisplatin (CDDP) in patients with advanced or metastatic pancreatic cancer. A multicenter randomized trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05962) by Levi (2004)
  36. 10.1016/S0360-3016(03)00435-8 / International Journal of Radiation Oncology Biology Physics / Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study by Li (2003)
  37. 10.1200/jco.2004.22.14_suppl.4144 / Proceedings of the American Society of Clinical Oncology / A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer by Li (2004)
  38. {'key': '10.1002/14651858.CD002093.pub2-BIB37|cit38', 'series-title': 'Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium', 'first-page': '(Abstract 140)', 'article-title': 'A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer', 'author': 'Li', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium / A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer by Li (2004)
  39. {'key': '10.1002/14651858.CD002093.pub2-BIB40|cit39', 'first-page': 'Abstract 1004', 'article-title': 'Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma : Interim results of the GERCOR /GISCAD Intergroup Phase III', 'volume': '22', 'author': 'Louvet', 'year': '2003', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma : Interim results of the GERCOR /GISCAD Intergroup Phase III by Louvet (2003)
  40. 10.1200/jco.2004.22.14_suppl.4008 / Proceedings of the American Society of Clinical Oncology / GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR /GISCAD Intergroup Phase III by Louvet (2004)
  41. 10.1200/JCO.2005.06.023 / Journal of Clinical Oncology / Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial by Louvet (2005)
  42. 10.1200/JCO.2002.09.029 / Journal of Clinical Oncology / Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer by Maisey (2002)
  43. 10.1136/bmj.281.6255.1589 / British Medical Journal / Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial by Mallinson (1980)
  44. 10.1016/S0140-6736(69)92326-5 / Lancet / Combined 5-flurouracil and supervoltage radiation therapy of locally uunresectable gastrointestinal cancer by Moertel CG. Childs DS. Reitemeier (1969)
  45. {'issue': '2', 'key': '10.1002/14651858.CD002093.pub2-BIB45|cit45', 'first-page': '205', 'article-title': 'A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group', 'volume': '189', 'year': '1979', 'journal-title': 'Annals of Surgery'} / Annals of Surgery / A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group (1979)
  46. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4 / Cancer / Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group by Moertel (1981)
  47. {'key': '10.1002/14651858.CD002093.pub2-BIB47|cit47', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4006', 'article-title': 'A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC)', 'author': "O'Reilly", 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) by O'Reilly (2004)
  48. 10.1093/annonc/mdi309 / Annals of Oncology / A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer by Oettle (2005)
  49. {'key': '10.1002/14651858.CD002093.pub2-BIB49|cit49', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4007', 'article-title': 'A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer', 'author': 'Richards', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer by Richards (2004)
  50. {'key': '10.1002/14651858.CD002093.pub2-BIB50|cit50', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4131', 'article-title': 'Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer', 'author': 'Ohkawa', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer by Ohkawa (2004)
  51. 10.1002/1097-0142(19860101)57:1<29::AID-CNCR2820570108>3.0.CO;2-L / Cancer / Chemotherapy for advanced pancreatic cancer. A comparison of 5- fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM) by Oster (1986)
  52. 10.1002/bjs.1800810629 / British Journal of Surgery / Chemotherapy prolongs survival in inoperable pancreatic carcinoma by Palmer (1994)
  53. 10.1016/S1470-2045(05)70175-3 / The Lancet Oncology / Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial by Reni (2005)
  54. 10.1200/jco.2004.22.14_suppl.4010 / Proceedings of the American Society of Clinical Oncology / Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA) by Reni (2004)
  55. 10.1200/jco.2004.22.14_suppl.4010 / Proceedings of the American Society of Clinical Oncology / Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA) by Reni (2004)
  56. {'key': '10.1002/14651858.CD002093.pub2-BIB56|cit56', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract LBA400', 'article-title': 'A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer', 'author': 'Riess', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology / A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer by Riess (2005)
  57. {'key': '10.1002/14651858.CD002093.pub2-BIB57|cit57', 'first-page': '(Abstract 107)', 'article-title': 'Gemcitabine and irinotecan (IRINOGEM) increases response rate compared to gemcitabine alone (GEM) in a randomized phase III study in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy', 'volume': '1', 'author': 'Rocha Lima', 'year': '2004', 'journal-title': 'Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium'} / Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium / Gemcitabine and irinotecan (IRINOGEM) increases response rate compared to gemcitabine alone (GEM) in a randomized phase III study in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy by Rocha Lima (2004)
  58. {'key': '10.1002/14651858.CD002093.pub2-BIB58|cit58', 'first-page': 'Abstract 1005', 'article-title': 'A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy', 'volume': '2003', 'author': 'Rocha Lima', 'year': '22', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy by Rocha Lima (22)
  59. 10.1200/JCO.2004.12.082 / Journal of Clinical Oncology / Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate by Rocha Lima (2004)
  60. 10.1093/annonc/mdg029 / Annals of Oncology / Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial by Scheithauer (2003)
  61. 10.1016/S0360-3016(01)02806-1 / International Journal of Radiation Oncology Biology Physics / Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer by Shinchi (2002)
  62. {'key': '10.1002/14651858.CD002093.pub2-BIB62|cit62', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4106', 'article-title': 'A randomized phase III study of Irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer', 'author': 'Stathopoulos', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology / A randomized phase III study of Irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer by Stathopoulos (2005)
  63. {'key': '10.1002/14651858.CD002093.pub2-BIB63|cit63', 'first-page': '707', 'article-title': 'Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract', 'volume': '23', 'author': 'Takada', 'year': '1996', 'journal-title': 'Gan To Kagaku Ryoho'} / Gan To Kagaku Ryoho / Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract by Takada (1996)
  64. {'issue': '24', 'key': '10.1002/14651858.CD002093.pub2-BIB64|cit64', 'first-page': '2020', 'article-title': 'Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial', 'volume': '45', 'author': 'Takada', 'year': '1998', 'journal-title': 'Hepatogastroenterology'} / Hepatogastroenterology / Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial by Takada (1998)
  65. 10.1038/bjc.1991.265 / British Journal of Cancer / Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas by Topham (1991)
  66. 10.1159/000227250 / Oncology / Comparison of single-agent epirubicin and 5- fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas by Topham (1993)
  67. {'key': '10.1002/14651858.CD002093.pub2-BIB67|cit67', 'first-page': 'Abstract 616', 'article-title': 'Gemcitabine (G) or gemcitabine plus cisplatin (GC) as first-line treatment in Chinese patients (pts) with locally advanced (LAPC) and metastatic pancreatic cancer (MPC): a multicenter, randomized, study', 'volume': '21', 'author': 'Wang', 'year': '2002', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Gemcitabine (G) or gemcitabine plus cisplatin (GC) as first-line treatment in Chinese patients (pts) with locally advanced (LAPC) and metastatic pancreatic cancer (MPC): a multicenter, randomized, study by Wang (2002)
  68. {'issue': '4', 'key': '10.1002/14651858.CD002093.pub2-BIB68|cit68', 'first-page': '404', 'article-title': 'Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer', 'volume': '24', 'author': 'Wang', 'year': '2002', 'journal-title': 'Zhonghua Zhong Liu Za Zhi'} / Zhonghua Zhong Liu Za Zhi / Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer by Wang (2002)
  69. {'issue': '22', 'key': '10.1002/14651858.CD002093.pub2-BIB69|cit69', 'first-page': '1125', 'article-title': 'Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study', 'volume': '45', 'author': 'Aigner', 'year': '1998', 'journal-title': 'Hepatogastroenterology'} / Hepatogastroenterology / Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study by Aigner (1998)
  70. 10.1093/annonc/mdi324 / Annals of Oncology / PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma:a North Central Cancer Treatment Group (NCCTG) randomized phase II study by Alberts (2005)
  71. 10.1097/00000421-199404000-00016 / American Journal of Clinical Oncology / An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer by Asbury (1994)
  72. 10.1023/A:1008299429294 / Annals of Oncology / Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid- Atlantic Oncology Program Study by Auerbach (1997)
  73. 10.1200/JCO.2001.19.15.3447 / Journal Clinical Oncology / Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial by Bramhall (2001)
  74. 10.1038/sj.bjc.6600446 / British Journal Cancer / A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer by Bramhall (2002)
  75. 10.1002/1097-0142(19930115)71:2<322::AID-CNCR2820710209>3.0.CO;2-G / Cancer / Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study by Bukowski (1993)
  76. 10.1038/bjc.1995.19 / British Journal of Cancer / A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy ] by Cascinu (1995)
  77. {'issue': 'S5', 'key': '10.1002/14651858.CD002093.pub2-BIB77|cit77', 'first-page': 'Abstract 222', 'article-title': 'Gastrazole, a novel CCK B/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials', 'volume': '1', 'author': 'Chau', 'year': '2003', 'journal-title': 'European Journal of Cancer'} / European Journal of Cancer / Gastrazole, a novel CCK B/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials by Chau (2003)
  78. 10.1016/j.canlet.2005.03.027 / Cancer Letters / The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression by Chen (2006)
  79. {'key': '10.1002/14651858.CD002093.pub2-BIB79|cit79', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': '250a', 'article-title': 'Randomised Trial of Gemcitabine (GEM) alone or with cisplatin (CDDP) for the treatment advanced pancreatic carcinoma (APC): a phase II multicentre study of the Southern Italian Oncology Group', 'author': 'Colucci', 'year': '1999'} / Proceedings of the American Society of Clinical Oncology / Randomised Trial of Gemcitabine (GEM) alone or with cisplatin (CDDP) for the treatment advanced pancreatic carcinoma (APC): a phase II multicentre study of the Southern Italian Oncology Group by Colucci (1999)
  80. {'key': '10.1002/14651858.CD002093.pub2-BIB80|cit80', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4151', 'article-title': 'A prospective and randomised clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an initial therapy of advanced pancreatic cancer', 'author': 'Ebert', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / A prospective and randomised clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an initial therapy of advanced pancreatic cancer by Ebert (2004)
  81. {'key': '10.1002/14651858.CD002093.pub2-BIB81|cit81', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 2511', 'article-title': 'Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy', 'author': 'Gilliam', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy by Gilliam (2004)
  82. {'issue': '4', 'key': '10.1002/14651858.CD002093.pub2-BIB82|cit82', 'first-page': '417', 'article-title': 'Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group', 'volume': '69', 'year': '1985', 'journal-title': 'Cancer Treatment Reports'} / Cancer Treatment Reports / Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group (1985)
  83. {'key': '10.1002/14651858.CD002093.pub2-BIB83|cit83', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4108', 'article-title': 'Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer', 'author': 'Heinemann', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer by Heinemann (2004)
  84. {'key': '10.1002/14651858.CD002093.pub2-BIB84|cit84', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4013', 'article-title': 'A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study', 'author': 'Jacobs', 'year': '2004'} / Proceedings of the American Society of Clinical Oncology / A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study by Jacobs (2004)
  85. 10.1046/j.0007-1323.2001.01770.x / British Journal of Surgery / Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma by Johnson (2001)
  86. {'issue': '6', 'key': '10.1002/14651858.CD002093.pub2-BIB86|cit86', 'first-page': '305', 'article-title': 'Radiation therapy with and without chemotherapy in the treatment of localized unresectable pancreatic carcinoma. A retrospective analysis', 'volume': '85', 'author': 'Jones', 'year': '1987', 'journal-title': 'Journal of the Kentucky Medical Association'} / Journal of the Kentucky Medical Association / Radiation therapy with and without chemotherapy in the treatment of localized unresectable pancreatic carcinoma. A retrospective analysis by Jones (1987)
  87. {'key': '10.1002/14651858.CD002093.pub2-BIB87|cit87', 'series-title': 'Z-GASTROENTEROL', 'first-page': '534', 'article-title': 'Palliative chemotherapy of pancreatic carcinoma. A prospective randomized study with 5-FU + BCNU and FAM', 'author': 'Klapdor', 'year': '1982'} / Z-GASTROENTEROL / Palliative chemotherapy of pancreatic carcinoma. A prospective randomized study with 5-FU + BCNU and FAM by Klapdor (1982)
  88. {'key': '10.1002/14651858.CD002093.pub2-BIB88|cit88', 'series-title': 'XIV meeting of the European Pancreatic Club', 'first-page': '43', 'article-title': 'Palliative treatment of pancreatic carcinoma with 5-FU + BCNU and FAM: a prospective randomised study', 'author': 'Klapdor', 'year': '1982'} / XIV meeting of the European Pancreatic Club / Palliative treatment of pancreatic carcinoma with 5-FU + BCNU and FAM: a prospective randomised study by Klapdor (1982)
  89. {'issue': '4', 'key': '10.1002/14651858.CD002093.pub2-BIB89|cit89', 'first-page': '875', 'article-title': 'Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer', 'volume': '7', 'author': 'Klein', 'year': '2000', 'journal-title': 'Oncology Reports'} / Oncology Reports / Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer by Klein (2000)
  90. {'issue': '4 Pt 1', 'key': '10.1002/14651858.CD002093.pub2-BIB90|cit90', 'first-page': '997', 'article-title': 'Clinical study on combination chemotherapy of primary liver cancer', 'volume': '10', 'author': 'Kojima', 'year': '1983', 'journal-title': 'Gan To Kagaku Ryoho'} / Gan To Kagaku Ryoho / Clinical study on combination chemotherapy of primary liver cancer by Kojima (1983)
  91. {'key': '10.1002/14651858.CD002093.pub2-BIB91|cit91', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 608', 'article-title': 'Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas', 'author': 'Lersch', 'year': '2001'} / Proceedings of the American Society of Clinical Oncology / Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas by Lersch (2001)
  92. 10.1097/00000658-197404000-00012 / Annals of Surgery / Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis- (2 chloroethyl)-1-nitrosourea (BCNU) by Lokich (1974)
  93. {'key': '10.1002/14651858.CD002093.pub2-BIB93|cit93', 'first-page': '1039', 'article-title': 'Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma', 'volume': '42', 'author': 'Lygidakis', 'year': '1995', 'journal-title': 'Hepato-Gastroenterology'} / Hepato-Gastroenterology / Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma by Lygidakis (1995)
  94. 10.1002/1097-0142(19801001)46:7<1518::AID-CNCR2820460703>3.0.CO;2-S / Cancer / 5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study by McCracken (1980)
  95. 10.1200/JCO.2003.02.098 / Journal of Clinical Oncology / Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group by Moore (2003)
  96. 10.1200/jco.2005.23.16_suppl.1 / Proceedings of the American Society of Clinical Oncology / Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] by Moore (2005)
  97. {'key': '10.1002/14651858.CD002093.pub2-BIB97|cit97', 'series-title': 'Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium', 'first-page': 'Abstract 77', 'article-title': 'Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group', 'author': 'Moore', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium / Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group by Moore (2005)
  98. {'key': '10.1002/14651858.CD002093.pub2-BIB98|cit98', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 4031', 'article-title': 'Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)', 'author': 'Oettle', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology / Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) by Oettle (2005)
  99. Imrie CW Mallinson CN Soukop M Thomas G Phase III study of 5 fluorouracil and epirubicin versus normal supportive treatment Pancreatic Society of Great Britain (Clinical Trial Protocol) 1989
  100. {'key': '10.1002/14651858.CD002093.pub2-BIB100|cit100', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract 644', 'article-title': 'Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC)', 'author': 'Richards', 'year': '2002'} / Proceedings of the American Society of Clinical Oncology / Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC) by Richards (2002)
  101. 10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4 / Cancer / Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report by Schein (1978)
  102. {'key': '10.1002/14651858.CD002093.pub2-BIB102|cit102', 'series-title': 'Proceedings of the American Society of Clinical Oncology', 'first-page': 'Abstract LBA401', 'article-title': 'G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study', 'author': 'Shapiro', 'year': '2005'} / Proceedings of the American Society of Clinical Oncology / G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study by Shapiro (2005)
  103. 10.1001/archinte.1978.03630250077022 / Archives of Internal Medicine / Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study by Stephens (1978)
  104. {'issue': '5', 'key': '10.1002/14651858.CD002093.pub2-BIB104|cit104', 'first-page': '1031', 'article-title': '5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes', 'volume': '59', 'author': 'Stolinsky', 'year': '1975', 'journal-title': 'Cancer Chemotherapy Reports'} / Cancer Chemotherapy Reports / 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes by Stolinsky (1975)
  105. 10.1097/00006676-200404000-00023 / Pancreas / Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer by Sunamura (2004)
  106. {'issue': '9', 'key': '10.1002/14651858.CD002093.pub2-BIB106|cit106', 'first-page': '1295', 'article-title': 'Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract', 'volume': '19', 'author': 'Takada', 'year': '1992', 'journal-title': 'Gan To Kagaku Ryoho'} / Gan To Kagaku Ryoho / Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract by Takada (1992)
  107. 10.1159/000227373 / Oncology / Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas by Takada (1994)
  108. 10.1200/JCO.2003.09.140 / Journal of Clinical Oncology / Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma by Tempero (2003)
  109. 10.1038/sj.bjc.6600883 / British Journal of Cancer / Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma by Ulrich-Pur (2003)
  110. {'key': '10.1002/14651858.CD002093.pub2-BIB110|cit110', 'first-page': 'Abstract 517', 'article-title': 'Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC)', 'volume': '21', 'author': 'Cutsem', 'year': '2002', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) by Cutsem (2002)
  111. 10.1200/JCO.2004.10.112 / Journal of Clinical Oncology / Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer by Cutsem (2004)
  112. 10.1016/S0959-8049(01)00319-7 / European Journal of Cancer / Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial by Wagener (2002)
  113. {'issue': '5-6', 'key': '10.1002/14651858.CD002093.pub2-BIB113|cit113', 'first-page': '179', 'article-title': 'Ukrain (NSC-631570) in the treatment of pancreas cancer', 'volume': '26', 'author': 'Zemskov', 'year': '2000', 'journal-title': 'Drugs under Experimental and Clinical Research'} / Drugs under Experimental and Clinical Research / Ukrain (NSC-631570) in the treatment of pancreas cancer by Zemskov (2000)
  114. 10.1016/j.ijrobp.2004.12.074 / International Journal of Radiation Oncology Biology Physics / A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282 by Cohen (2005)
  115. {'key': '10.1002/14651858.CD002093.pub2-BIB115|cit115', 'series-title': 'European Journal of Cancer Supplements', 'first-page': 'PS11', 'article-title': 'Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer', 'author': 'Cunningham', 'year': '2005'} / European Journal of Cancer Supplements / Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer by Cunningham (2005)
  116. Randomized phase III trial of gemcitabine plus bevacizumab vs. gemcitabine plus placebo in patients with advanced pancreatic cancer Ongoing study
  117. Phase II randomised study of gemcitabine alone vs gemcitabine with cisplatin vs gemcitabine with Docetaxel vs gemcitabine with irinotecan in patients With metastatic pancreatic cancer Ongoing study
  118. Phase III randomised study of gemcitabine with or without radiotherapy in patients with locally advanced, unresectable pancreatic cancer Ongoing study
  119. Phase III randomised study of standard infusion gemcitabine vs prolonged infusion gemcitabine with or without oxaliplatin patients with locally advanced or metastatic pancreatic cancer. Ongoing study
  120. Phase II randomised study of irinotecan and docetaxel with or without cetuximab in patients with metastatic adenocarcinoma of the pancreas. Ongoing study
  121. Phase III trial of docetaxel/gemcitabine vs gemcitabine in advanced pancreatic cancer. Ongoing study
  122. Phase III randomised multicentre trial of infusional fluorouracil with or without cisplatin and with or without chronomodulation against locally advanced or metastatic pancreatic cancer. Ongoing study
  123. Phase III randomised study of gemcitabine with or without oxaliplatin in patients with locally or advanced or metastatic unresectable pancreatic cancer. Ongoing study
  124. {'key': '10.1002/14651858.CD002093.pub2-BIB124|cit124', 'series-title': 'Proc Am Soc Clin Oncol', 'first-page': 'Abstract 4030', 'article-title': 'Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx) : A randomized phase II trial in advanced pancreatic cancer', 'author': 'Heinemann', 'year': '2005'} / Proc Am Soc Clin Oncol / Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx) : A randomized phase II trial in advanced pancreatic cancer by Heinemann (2005)
  125. Phase III randomised study of gemcitabine with or without virulizin followed by optional secondline therapy with virulizin or placebo with or without fluorouracil in patients with chemotherapy-naive locally-advanced or metastatic pancreatic cancer. Ongoing study
  126. Phase II randomised study of gemcitabine vs immunotherapy with CYTOIMPLANT as first line therapy in patients with unresectable, locally advanced or metastatic pancreatic cancer. Ongoing study
  127. A randomised trial of CF (Infusional 5-Fluorouracil and Cisplatin) alone versus CF plus concurrent radiotherapy in patients with locally advanced pancreatic carcinoma Ongoing study
  128. Phase II randomized study of bortezomib with or without gemcitabine in patients with metastatic pancreatic adenocarcinoma Ongoing study
  129. Phase II randomised study of bevacizumab and gemcitabine with either cetuximab or erlotinib in patients with advanced adenocarcinoma of the pancreas. Ongoing study
  130. A randomised, phase II, study of TNFerade™ biologic with 5-FU and radiation therapy for first-line treatment of unresectable locally advanced pancreatic cancer Ongoing study
  131. Randomised phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally-advanced pancreatic cancer. Ongoing study
  132. Phase III randomised open label study comparing gemcitabine with cetuximab vs gemcitabine as first line therapy of patients with advanced pancreatic carcinoma. Ongoing study
  133. Phase III randomised controlled study to evaluate the safety and efficacy of PANVAC-VF in combination with GM-CSF vs best supportive care or palliative chemotherapy in patients with metastatic adenocarcinoma of the pancreas who have failed a gemcitabine containing chemotherapy regimen. Ongoing study
  134. Study of efficacy and safety of glufosfamide compared with best supportive care in metastatic pancreatic cancer Ongoing study
  135. Phase III randomised study of triacetyleluridine and high dose fluorouracil versus gemcitabine in patients with unresectable locally-advanced or metastatic pancreatic cancer. Ongoing study
  136. 10.1111/j.1749-6632.2002.tb04105.x / Annals of the New York Academy of Science / Objective response to treatment as a potential surrogate marker of survival in breast cancer by Bruzzi (2002)
  137. 10.1016/S0140-6736(00)02528-9 / Lancet / Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer by Buyse (2000)
  138. 10.1097/00000658-199603000-00007 / Annals of Surgery / Long term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors by Conlon (1996)
  139. {'issue': '8', 'key': '10.1002/14651858.CD002093.pub2-BIB139|cit139', 'first-page': '1101', 'article-title': 'Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)', 'volume': '30', 'author': 'Fung', 'year': '2003', 'journal-title': 'Gan To Kagaku Ryoho'} / Gan To Kagaku Ryoho / Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002) by Fung (2003)
  140. 10.1016/S0002-9610(05)80406-4 / American Journal of Surgery / Prognostic indicators for survival after resection of pancreatic adenocarcinoma by Geer (1993)
  141. {'issue': '3', 'key': '10.1002/14651858.CD002093.pub2-BIB141|cit141', 'article-title': 'Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]', 'author': 'Higgins', 'year': '2005', 'journal-title': 'The Cochrane Library'} / The Cochrane Library / Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] by Higgins (2005)
  142. 10.3322/canjclin.55.1.10 / CA: a Cancer Journal for Clinicians / Cancer statistics, 2005 by Jemal (2005)
  143. 10.1097/00000658-200301000-00011 / Annals of Surgery / Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients by Lim (2003)
  144. 10.1056/NEJMoa032295 / New England Journal of Medicine / A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer by Neoptolemos (2004)
  145. 10.3322/canjclin.55.2.74 / CA: a Cancer Journal for Clinicians / Global cancer statistics, 2002 by Parkin (2005)
  146. {'issue': 'Suppl 4', 'key': '10.1002/14651858.CD002093.pub2-BIB146|cit146', 'first-page': 'Abstract 911P', 'article-title': 'Quality of life outcome in advanced pancreatic adenocarcinoma:results from a phase III trial', 'volume': '15', 'author': 'Reni', 'year': '2004', 'journal-title': 'Annals of Oncology'} / Annals of Oncology / Quality of life outcome in advanced pancreatic adenocarcinoma:results from a phase III trial by Reni (2004)
  147. 10.1016/S1072-7515(99)00075-7 / Journal of the American College of Surgeons / Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database by Sener (1999)
  148. {'key': '10.1002/14651858.CD002093.pub2-BIB148|cit148', 'first-page': '269', 'article-title': 'Carcinoma of the pancreas: resection outcome at the University Hospital Kuala Lumpur', 'volume': '82', 'author': 'Shahrudin', 'year': '1997', 'journal-title': 'International Surgery'} / International Surgery / Carcinoma of the pancreas: resection outcome at the University Hospital Kuala Lumpur by Shahrudin (1997)
  149. 10.1038/sj.bjc.6602513 / British Journal of Cancer / Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer by Stocken (2005)
  150. 10.1097/00000658-199004000-00011 / Annals of Surgery / Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality by Trede (1990)
  151. 10.1002/bjs.4484 / British Journal of Surgery / Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma by Wagner (2004)
  152. 10.1007/s00268-004-7338-z / World Journal of Surgery / Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer by Wilkowski (2004)
  153. 10.1097/00000658-199709000-00004 / Annals of Surgery / Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes by Yeo (1997)
Dates
Type When
Created 19 years, 1 month ago (July 18, 2006, 12:38 p.m.)
Deposited 4 years ago (Aug. 9, 2021, 1:09 p.m.)
Indexed 1 month, 1 week ago (July 26, 2025, 5:24 a.m.)
Issued 19 years, 1 month ago (July 19, 2006)
Published 19 years, 1 month ago (July 19, 2006)
Published Online 19 years, 1 month ago (July 19, 2006)
Funders 0

None

@misc{Yip_2006, title={Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer}, url={http://dx.doi.org/10.1002/14651858.cd002093.pub2}, DOI={10.1002/14651858.cd002093.pub2}, journal={Cochrane Database of Systematic Reviews}, publisher={John Wiley & Sons, Ltd}, author={Yip, Desmond and Karapetis, Christos and Strickland, Andrew and Steer, Christopher B and Goldstein, David}, editor={Yip, Desmond}, year={2006}, month=jul }